Leerink Partnrs Brokers Lower Earnings Estimates for ARDT

Ardent Health Partners, LLC (NYSE:ARDT) – Leerink Partnrs decreased their Q1 2025 earnings estimates for shares of Ardent Health Partners in a report issued on Monday, November 11th. Leerink Partnrs analyst W. Mayo now expects that the company will post earnings per share of $0.35 for the quarter, down from their previous estimate of $0.39. Leerink Partnrs has a “Strong-Buy” rating on the stock. The consensus estimate for Ardent Health Partners’ current full-year earnings is $1.25 per share. Leerink Partnrs also issued estimates for Ardent Health Partners’ Q2 2025 earnings at $0.58 EPS, Q3 2025 earnings at $0.49 EPS, Q4 2025 earnings at $0.56 EPS, FY2025 earnings at $1.99 EPS, FY2026 earnings at $2.27 EPS and FY2027 earnings at $2.51 EPS.

Ardent Health Partners (NYSE:ARDT) last released its earnings results on Wednesday, August 14th. The company reported $0.35 EPS for the quarter, beating the consensus estimate of $0.30 by $0.05. The company had revenue of $1.47 billion for the quarter, compared to analyst estimates of $1.46 billion.

ARDT has been the subject of several other research reports. Royal Bank of Canada restated an “outperform” rating and set a $23.00 price objective on shares of Ardent Health Partners in a research report on Thursday. Truist Financial assumed coverage on shares of Ardent Health Partners in a research report on Monday, August 12th. They set a “buy” rating and a $21.00 price objective for the company. KeyCorp assumed coverage on shares of Ardent Health Partners in a research report on Friday, October 11th. They set an “overweight” rating and a $24.00 price objective for the company. JPMorgan Chase & Co. assumed coverage on shares of Ardent Health Partners in a research report on Monday, August 12th. They set a “neutral” rating and a $18.00 price objective for the company. Finally, Bank of America lowered shares of Ardent Health Partners from a “buy” rating to a “neutral” rating and reduced their price objective for the company from $22.00 to $19.00 in a research report on Wednesday, November 6th. Two equities research analysts have rated the stock with a hold rating, eight have assigned a buy rating and two have assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Buy” and an average target price of $21.82.

Ardent Health Partners Price Performance

Ardent Health Partners stock opened at $17.81 on Thursday. The company has a debt-to-equity ratio of 0.78, a quick ratio of 1.78 and a current ratio of 1.91. The firm’s 50-day moving average is $18.27. Ardent Health Partners has a 52 week low of $14.57 and a 52 week high of $20.72.

Institutional Trading of Ardent Health Partners

Several institutional investors have recently made changes to their positions in ARDT. Goldentree Asset Management LP acquired a new stake in shares of Ardent Health Partners during the third quarter worth approximately $22,897,000. Allspring Global Investments Holdings LLC acquired a new stake in shares of Ardent Health Partners during the third quarter worth approximately $13,119,000. Seven Grand Managers LLC acquired a new stake in shares of Ardent Health Partners during the third quarter worth approximately $2,298,000. Charles Schwab Investment Management Inc. acquired a new stake in shares of Ardent Health Partners during the third quarter worth approximately $526,000. Finally, MetLife Investment Management LLC acquired a new stake in shares of Ardent Health Partners during the third quarter worth approximately $135,000.

Ardent Health Partners Company Profile

Ardent Health Partners, Inc owns and operates a network of hospitals and clinics that provides a range of healthcare services in the United States. It operates acute care hospitals, including rehabilitation hospitals and surgical hospitals. The company was founded in 2001 and is based in Brentwood, Tennessee.